.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Fish and Richardson
Fuji
Teva
Medtronic
Novartis
Mallinckrodt
Express Scripts
Argus Health

Generated: September 22, 2017

DrugPatentWatch Database Preview

Veloxis Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for VELOXIS PHARMS INC, and what generic alternatives to VELOXIS PHARMS INC drugs are available?

VELOXIS PHARMS INC has one approved drug.

There are thirteen US patents protecting VELOXIS PHARMS INC drugs.

There are forty-six patent family members on VELOXIS PHARMS INC drugs in twenty-four countries.

Summary for Applicant: Veloxis Pharms Inc

Patents:13
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-001Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-003Jul 10, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-003Jul 10, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-001Jul 10, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-001Jul 10, 2015RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Veloxis Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,038,998► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Veloxis Pharms Inc Drugs

Country Document Number Estimated Expiration
Hong Kong1096032► Subscribe
Norway20061429► Subscribe
World Intellectual Property Organization (WIPO)2011100975► Subscribe
Poland2575769► Subscribe
Russian Federation2011104205► Subscribe
Norway334986► Subscribe
South Korea20110033262► Subscribe
Denmark1663217► Subscribe
Japan2007504102► Subscribe
Slovenia2575769► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Moodys
Harvard Business School
Mallinckrodt
Teva
Julphar
Cantor Fitzgerald
Fuji
Covington
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot